ASCP: American Society of Clinical Psychopharmacology
Conference Coverage
Novel female sexual dysfunction drug effective, phase III studies show
Bremelanotide, which is administered subcutaneously, addresses low female sexual desire that is biological in nature.
Conference Coverage
Treatment response rates for psychotic bipolar depression similar to those without
MIAMI – “If we make the patient better, it doesn’t matter which medication we use” to treat bipolar.
News
Sublingual cyclobenzaprine may be effective, safe for military-related PTSD
Key clinical point: Sublingual cyclobenzaprine improved sleep and reduced hyperarousal symptoms in military-related PTSD.
Conference Coverage
Alternative therapies can augment treatment in resistant depression
SCOTTSDALE, ARIZ. – Simple, effective, nonpharmacologic therapies can significantly augment pharmacotherapy for patients with treatment-resistant...
Conference Coverage
Low-field magnetic stimulation fails to improve refractory depression
Key clinical point: Low-field magnetic stimulation (LFMS) was no better than sham in improving treatment-resistant depression. Major finding: In a...
Conference Coverage
Does medical marijuana work for PTSD, other psychiatric indications?
Data scant on use of medical marijuana for PTSD, agitation in Alzheimer’s
Conference Coverage
Vilazodone significantly improved generalized anxiety disorder symptoms
Many symptoms of generalized anxiety disorder improved significantly for patients taking vilazodone, compared with placebo.
News
Bipolar disorder patients may underestimate their sleep quality
Sleep quality in patients with bipolar disorder may be better than they perceive it to be.
Conference Coverage
ASCP: Variable pattern of inflammation markers found in serious mental illness
Bipolar disorder, schizophrenia, and major depressive disorder appear to have separate and distinct patterns of inflammatory markers.
Conference Coverage
ASCP: Animal models, big data give mind/microbiome research a boost
Conference Coverage
ASCP: External trigeminal nerve stimulation improves treatment-resistant depression
A noninvasive procedure might help lift refractory depressive symptoms 2 weeks after the first treatment.
Conference Coverage
ASCP: Intranasal esketamine bests placebo for treatment-resistant depression
Key clinical point: Intranasal esketamine resulted in significant improvement of depression vs.
Conference Coverage
ASCP: Brain imaging findings provide new guidance for neural outcomes research
Key clinical point: Emotional disruptors to a cognitive attention task activated different brain regions, and emotional activation increased with...
Conference Coverage
ASCP: Structured community-based program improves early schizophrenia care
Key clinical point: A structured community-based program improved treatment in early schizophrenia. Major finding: Early results show that COMPASS...